Cargando…

Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections

INTRODUCTION: Childhood respiratory syncytial virus (RSV) infection is a global phenomenon that can lead to fatal respiratory illness. Palivizumab is a drug that is routinely used in affluent countries as a prophylaxis against RSV infection; nevertheless, breakthrough infections are often reported....

Descripción completa

Detalles Bibliográficos
Autores principales:	Jun, Shelly, Sebastianski, Meghan, Featherstone, Robin, Robinson, Joan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Paediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661690/ https://www.ncbi.nlm.nih.gov/pubmed/31340973 http://dx.doi.org/10.1136/bmjopen-2019-029832

Ejemplares similares

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

Does obstructive sleep apnoea contribute to obesity, hypertension and kidney dysfunction in children? A systematic review protocol
por: Rodriguez-Lopez, Sara, et al.
Publicado: (2020)

Does non-invasive ventilation change metabolic markers in children with obstructive sleep apnoea? A systematic review and meta-analysis study protocol
por: Gerdung, Christopher, et al.
Publicado: (2020)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Diagnostic models predicting paediatric viral acute respiratory infections: a systematic review
por: Rankin, Danielle A, et al.
Publicado: (2023)

Assessment of interferon gamma and indoleamine 2,3-dioxygenase 1 analysis during respiratory syncytial virus infection in infants in Italy: an observational case–control study
por: Savino, Francesco, et al.
Publicado: (2022)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
por: Edirisinghe, Hasindu S., et al.
Publicado: (2023)

Determinants of inter-practice variation in childhood asthma and respiratory infections: cross-sectional study of a national sentinel network
por: Hoang, Uy, et al.
Publicado: (2019)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high-risk Australian children: a whole-of-population-based cohort study
por: Homaira, Nusrat, et al.
Publicado: (2017)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
por: Antepowicz, Agata, et al.
Publicado: (2021)

Prevalence of and factors associated with childhood diarrhoeal disease and acute respiratory infection in Bangladesh: an analysis of a nationwide cross-sectional survey
por: Kundu, Satyajit, et al.
Publicado: (2022)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Description of the Outcomes of Prior Authorization of Palivizumab for Prevention of Respiratory Syncytial Virus Infection in a Managed Care Organization
por: Buckley, Brieana C., et al.
Publicado: (2010)

Treatment strategies for cerebrospinal shunt infections: a systematic review of observational studies
por: Robinson, Joan L, et al.
Publicado: (2020)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis
por: Fernandes, Ricardo M, et al.
Publicado: (2019)

Prospective observational study in two Dutch hospitals to assess the performance of inflammatory plasma markers to determine disease severity of viral respiratory tract infections in children
por: Ahout, Inge M L, et al.
Publicado: (2017)

Study protocol for a randomised controlled trial evaluating the clinical effect of antibiotic prophylaxis in children with recurrent respiratory tract infections: the Approach study
por: Peeters, Daphne, et al.
Publicado: (2021)

Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia
por: Al Aql, Fahad, et al.
Publicado: (2016)

Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
por: Ambrose, Christopher S.
Publicado: (2017)

Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study
por: Kamori, Akiko, et al.
Publicado: (2021)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan
por: Chi, Hsin, et al.
Publicado: (2014)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Daycare attendance and respiratory tract infections: a prospective birth cohort study
por: Schuez-Havupalo, Linnea, et al.
Publicado: (2017)

Long-term non-invasive ventilation therapies in children: a scoping review protocol
por: Castro Codesal, Maria L, et al.
Publicado: (2015)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
por: Silva, Camila de A, et al.
Publicado: (2012)

Study protocol epidemiology of inflammatory bowel disease in childhood and adolescence: a systematic review
por: Weidner, Jens, et al.
Publicado: (2020)

Study protocol of the Edinburgh and Lothian Virus Intervention Study in Kids: a randomised controlled trial of hypertonic saline nose drops in children with upper respiratory tract infections (ELVIS Kids)
por: Ramalingam, Sandeep, et al.
Publicado: (2021)

Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
por: Zhaori, Getu
Publicado: (2023)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit
por: Alan, S., et al.
Publicado: (2012)

Transforming Obesity Prevention for CHILDren (TOPCHILD) Collaboration: protocol for a systematic review with individual participant data meta-analysis of behavioural interventions for the prevention of early childhood obesity
por: Hunter, Kylie E, et al.
Publicado: (2022)

Unpacking the behavioural components and delivery features of early childhood obesity prevention interventions in the TOPCHILD Collaboration: a systematic review and intervention coding protocol
por: Johnson, Brittany J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6uptpmpnoldc6ifrcj91m7ms98